fenofibrate

fenofibrate
IUPAC name	propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
Width	200
CAS number	49562-28-9
DrugBank	DB01039
UNII	U202363UOS

fenofibrate is a fibric acid derivative medication primarily used to treat abnormal blood lipid levels. It is indicated to reduce elevated levels of triglycerides and low-density lipoprotein (LDL) cholesterol while increasing levels of high-density lipoprotein (HDL) cholesterol in adults. The drug is marketed under various brand names worldwide, including Tricor and Lipofen, and is often prescribed when statin therapy alone is insufficient or not tolerated.

Medical uses

Fenofibrate is approved by the U.S. Food and Drug Administration for the treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia, such as in Fredrickson classification types IIa and IIb. It is frequently used in conjunction with a statin, like atorvastatin or simvastatin, in patients with cardiovascular disease who require additional triglyceride-lowering, though this combination increases the risk of rhabdomyolysis. Clinical trials, including the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, have investigated its role in reducing cardiovascular events in specific populations, such as those with type 2 diabetes.

Adverse effects

Common adverse effects include dyspepsia, nausea, and rash. More serious risks involve hepatotoxicity, signaled by elevated liver function tests, and myopathy, which can progress to the severe muscle breakdown condition rhabdomyolysis, particularly when combined with other agents like gemfibrozil or certain statins. Fenofibrate use is associated with an increased incidence of pancreatitis, pulmonary embolism, and deep vein thrombosis in some studies, and it can cause cholelithiasis due to increased cholesterol excretion into bile. Renal impairment, including creatinine elevation, has been observed, necessitating dose adjustment in patients with chronic kidney disease.

Pharmacology

Fenofibrate acts as an agonist for the peroxisome proliferator-activated receptor alpha (PPAR-α), a nuclear receptor predominantly expressed in the liver, kidney, heart, and muscle. Activation of PPAR-α leads to increased transcription of genes involved in fatty acid oxidation and lipoprotein metabolism, such as lipoprotein lipase and apolipoprotein A-I. This results in enhanced clearance of very-low-density lipoprotein (VLDL) particles and reduced synthesis of triglycerides. The drug is a prodrug hydrolyzed by esterases in the body to its active form, fenofibric acid, which is then extensively bound to albumin.

Chemistry

Fenofibrate is chemically described as an isopropyl ester of fenofibric acid. Its systematic name is propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate. The compound is a white crystalline powder that is practically insoluble in water but soluble in organic solvents such as chloroform, methanol, and ethanol. The presence of the chlorobenzoyl moiety and the phenoxy group is central to its pharmacological activity. It is structurally related to other fibric acid derivatives like clofibrate and gemfibrozil.

History

Fenofibrate was developed in the 1970s by the French pharmaceutical company Laboratoires Fournier, which later became part of Solvay Pharmaceuticals. It received initial marketing authorization in France in 1975. The drug gained approval from the U.S. Food and Drug Administration in 1993. Its development was part of a broader class of hypolipidemic agents researched following the discovery of clofibrate. Over the decades, various formulations, including micronized and nanoparticle versions, were developed to improve its bioavailability.

Society and culture

Fenofibrate is available as a generic medication in many countries, significantly reducing its cost. Key brand names include Tricor (AbbVie), Lipofen (Kowa Company, Ltd.), and Fenoglide. It is listed on the World Health Organization Model List of Essential Medicines. The drug has been the subject of litigation, including patent disputes involving companies like Teva Pharmaceutical Industries and Mylan. Its use is guided by major clinical guidelines from organizations such as the American College of Cardiology and the American Heart Association.

Category:Drugs